Avadel Pharmaceuticals (AVDL) Projected to Post Earnings on Monday

Avadel Pharmaceuticals (NASDAQ:AVDL) is expected to be issuing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of $0.09 per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 4:00 PM ET.

Avadel Pharmaceuticals Trading Down 1.1%

Avadel Pharmaceuticals stock opened at $21.39 on Monday. Avadel Pharmaceuticals has a 12-month low of $6.38 and a 12-month high of $23.57. The firm has a 50 day simple moving average of $21.51 and a 200-day simple moving average of $18.73.

Hedge Funds Weigh In On Avadel Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AVDL. Raymond James Financial Inc. acquired a new stake in Avadel Pharmaceuticals during the 2nd quarter valued at $65,000. Tower Research Capital LLC TRC grew its holdings in shares of Avadel Pharmaceuticals by 217.5% during the second quarter. Tower Research Capital LLC TRC now owns 8,795 shares of the company’s stock valued at $78,000 after buying an additional 6,025 shares in the last quarter. Prudential Financial Inc. acquired a new position in Avadel Pharmaceuticals during the second quarter valued at $96,000. Dynamic Technology Lab Private Ltd acquired a new position in Avadel Pharmaceuticals during the first quarter valued at $115,000. Finally, CIBC Private Wealth Group LLC purchased a new stake in Avadel Pharmaceuticals in the 3rd quarter worth about $122,000. Institutional investors and hedge funds own 69.19% of the company’s stock.

Analyst Upgrades and Downgrades

AVDL has been the subject of a number of research reports. UBS Group lowered Avadel Pharmaceuticals to a “neutral” rating in a research note on Tuesday, October 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avadel Pharmaceuticals in a research note on Monday, December 29th. Wells Fargo & Company lifted their target price on Avadel Pharmaceuticals from $20.00 to $22.50 and gave the stock an “equal weight” rating in a report on Thursday, November 20th. Finally, Zacks Research raised shares of Avadel Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, January 6th. One research analyst has rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Avadel Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $20.00.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc is a global specialty biopharmaceutical company focused on developing and delivering treatments for rare diseases and central nervous system disorders. Headquartered in Dublin, Ireland, with operations in the United States, Avadel’s portfolio centers on sleep disorder therapeutics, including its flagship low-sodium oxybate product, XYWAV, which is approved in the U.S. for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy. The company is also advancing FT218, a once-nightly formulation of sodium oxybate, currently under regulatory review for narcolepsy management.

Formed through a rebranding of Flamel Technologies in 2016 and a strategic shift toward rare disease drug development, Avadel has built its R&D capabilities around improving patient compliance and reducing daily sodium exposure compared to traditional therapies.